Vestmark Advisory Solutions Inc. Reduces Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Vestmark Advisory Solutions Inc. decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 47.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,229 shares of the medical device company’s stock after selling 2,867 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in DexCom were worth $251,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Freestone Capital Holdings LLC lifted its stake in DexCom by 19.0% in the fourth quarter. Freestone Capital Holdings LLC now owns 22,780 shares of the medical device company’s stock worth $1,772,000 after acquiring an additional 3,637 shares during the period. Ethos Financial Group LLC bought a new position in DexCom in the fourth quarter worth $539,000. Lindbrook Capital LLC raised its holdings in DexCom by 247.3% in the fourth quarter. Lindbrook Capital LLC now owns 1,740 shares of the medical device company’s stock worth $135,000 after purchasing an additional 1,239 shares in the last quarter. Inceptionr LLC raised its holdings in DexCom by 18.4% in the fourth quarter. Inceptionr LLC now owns 8,533 shares of the medical device company’s stock worth $664,000 after purchasing an additional 1,324 shares in the last quarter. Finally, Cullen Frost Bankers Inc. raised its holdings in DexCom by 123.3% in the fourth quarter. Cullen Frost Bankers Inc. now owns 4,851 shares of the medical device company’s stock worth $377,000 after purchasing an additional 2,679 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,083 shares of company stock valued at $3,309,794. Insiders own 0.30% of the company’s stock.

DexCom Price Performance

NASDAQ DXCM opened at $77.84 on Monday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The stock has a 50-day moving average of $84.83 and a 200 day moving average of $77.01. The company has a market capitalization of $30.42 billion, a price-to-earnings ratio of 54.43, a PEG ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, sell-side analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

DXCM has been the subject of a number of research reports. Canaccord Genuity Group increased their price objective on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Morgan Stanley increased their price objective on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a report on Friday, February 14th. Citigroup increased their price objective on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and raised their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Four research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.